Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs has filed a non-traditional product license application (PLA) for Travelan, an over-the-counter product for the prevention of travellers' diarrhea, and has been accepted by Health Canada for review.
Subscribe to our email newsletter
Travelan is a natural product which is designed to reduce the risk of infection by ETEC, the most common cause of Travellers’ Diarrhea.
Paladin Labs interim president and chief executive officer Mark Beaudet said, "Most OTC products on the market today only treat the symptoms of traveller’s diarrhea. We expect that Travelan will benefit Canadians because it helps prevent traveller’s diarrhea before it even begins."
In clinical trials, Travelan showed protection of up to 90% efficacy against infection with the type of E.coli that causes Travellers’ Diarrhea.
Travelan is currently approved in Australia, New Zealand and South Africa.
In November 2011, Paladin gained exclusive rights to market and sell Travelan in Canada, Latin America and Sub-Saharan Africa from Immuron.